BioSpace News Archive

Thermo Fisher Scientific, the world leader in serving science, and the University of Sheffield, a leading institution with a global reputation for research excellence, have joined forces to develop advanced end-to-end workflows for the characterization and monitoring of complex oligonucleotide and mRNA products

Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), today announced that results from two post-hoc analyses from the clinical development program for WAKIX® (pitolisant) will be presented at the 35th Annual Meeting of the Associated Professional Sleep Societies

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the Food and Drug Administration recently accepted Amneal’s 505(b)(2) New Drug Application for a newly licensed dihydroergotamine (DHE) prefilled syringe autoinjector and the company said it anticipates a decision by the middle of 2022

Privately-held company Guard Medical Inc. today announces enrollment of the first five patients in the post-market study of its NPsealTM at Keck Medical Center of USC.

Cergentis and collaborators publish a method for accurate and automatic detection of clinically relevant translocations in tumor biopsies

Soleo Health, an innovative leader and national provider of complex specialty pharmacy and infusion services, announced its Phoenix, Arizona location has earned Specialty Pharmacy Accreditation from URAC, the leading independent accrediting organization focused on supporting the quality of health care through leadership, accreditation, measurement and innovation standards and programs.

Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced that it will be holding a Virtual Investor Event on Tuesday, June 22, 2021, at 9:00 a.m. - 11:00 a.m. EDT / 3:00 p.m. - 5:00 p.m. CEST.

DUBLIN, Ireland, and Boston MA, June 7, 2021, Amryt, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces that the U.S. Food and Drug Administration has confirmed that Amryt’s New Drug Application for Oleogel-S10 for the treatment of Epidermolysis Bullosa will not require an Advisory Committee meeting.

Equipment transfer positions Prodigy to expedite production expansion and next-generation disease-resistant silkworms